 |  |
 | |
 |
TWINRIX, the only hepatitis A and hepatitis B combination vaccine available in the United States, is available on a dosing schedule of three doses within three weeks followed by a booster dose at 12 months. The dosing schedule is Day 0, Day 7, Days 21-31, and a booster dose at 12 months. The accelerated dosing delivers a sustained immune response. [1] Learn more |
 |
|
|  TWINRIX is indicated for active immunization of persons 18 years of age or older against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus. Important Safety Information TWINRIX is contraindicated in people with hypersensitivity to any component of the vaccine, including yeast and neomycin.In clinical trials with TWINRIX, the most common solicited adverse events were: They were mild and self-limiting and did not last more than 48 hours. As with any vaccine, rare adverse events may occur. (See Adverse Reactions section of the Prescribing Information for TWINRIX for other potential side effects.) As with any vaccine, TWINRIX may not protect 100% of individuals receiving the vaccine. Please see complete Prescribing Information for TWINRIX. ReferencesTWINRIX and Tip-Lok are registered trademarks of GlaxoSmithKline. Manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709 |
|
This site is intended for US healthcare professionals only. © 1997-2008 GlaxoSmithKline. All Rights Reserved. |